See more : Barloworld Limited (BRRAF) Income Statement Analysis – Financial Results
Complete financial analysis of AzurRx BioPharma, Inc. (AZRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AzurRx BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Regal Hotels International Holdings Limited (0078.HK) Income Statement Analysis – Financial Results
- Katipult Technology Corp. (KTPPF) Income Statement Analysis – Financial Results
- Canadian Utilities Limited (CDUUF) Income Statement Analysis – Financial Results
- Western Acquisition Ventures Corp. (WAVSW) Income Statement Analysis – Financial Results
- LiveOne, Inc. (LVO) Income Statement Analysis – Financial Results
AzurRx BioPharma, Inc. (AZRX)
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5,888.00B | 8.68M | 4.99M | 2.40M | 2.50M | 1.40M |
| General & Administrative | 7.29M | 6.06M | 8.24M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.29M | 6.06M | 8.24M | 0.00 | 0.00 | 0.00 |
| Other Expenses | 20,544.76B | 0.00 | 210.00K | 7.69M | 4.13M | -4.73M |
| Operating Expenses | 26,432.77B | 14.74M | 13.43M | 10.08M | 6.63M | -3.33M |
| Cost & Expenses | 26,432.77B | 14.74M | 13.43M | 10.08M | 6.63M | 4.73M |
| Interest Income | 484.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5,840.61B | 433.94K | 101.85K | 875.20K | 5.94M | 1.59M |
| Depreciation & Amortization | 37.80K | 1.02M | 798.45K | 754.00K | 734.50K | 733.60K |
| EBITDA | -26,830.85B | -13.72M | -12.63M | -9.47M | -7.92M | -3.61M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -26,432.77B | -14.74M | -13.43M | -10.08M | -6.63M | -4.73M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6,238.70B | -433.94K | -101.85K | -1.02M | -7.97M | -1.20M |
| Income Before Tax | -32,671.47B | -15.18M | -13.53M | -11.10M | -14.59M | -5.93M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -398.08B | 0.00 | 0.00 | -140.00K | -2.03M | 386.11K |
| Net Income | -32,671.47B | -15.18M | -13.53M | -11.10M | -14.59M | -5.93M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -5.90M | -6.77 | -8.77 | -10.44 | -22.43 | -6.16 |
| EPS Diluted | -5.90M | -6.77 | -8.77 | -10.44 | -22.43 | -6.16 |
| Weighted Avg Shares Out | 5.53M | 2.24M | 1.54M | 1.06M | 650.48K | 963.11K |
| Weighted Avg Shares Out (Dil) | 5.53M | 2.24M | 1.54M | 1.06M | 650.48K | 963.11K |
Hospital Acquired Infections (HAI) Diagnostics Market Trends 2020: Emerging Technologies, Sales Revenue, Key Players Analysis, Development Status, Opportunity Assessment and Industry Expansion Strategies 2023
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
AzurRx BioPharma Announces Pricing of Initial Public Offering
Source: https://incomestatements.info
Category: Stock Reports